Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 9/20 | 0.46 |
| ▸ | NPY1R | P25929 | 6/20 | 0.46 |
| ▸ | NPY2R | P49146 | 4/20 | 0.46 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.46 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.45 |
| ▸ | APLNR | P35414 | 2/20 | 0.45 |
| ▸ | GLP1R | P43220 | 1/20 | 0.43 |
| ▸ | SCTR | P47872 | 1/20 | 0.43 |
| ▸ | KISS1R | Q969F8 | 4/20 | 0.42 |
| ▸ | QRFPR | Q96P65 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30216757 | 1.00 | NPY4R (0.46) | NPY4RNPY1RNPY2RNPY5RC5AR1 | |
| SCHEMBL29958548 | 0.94 | NPY4R (0.49) | NPY4RNPY1RNPY2RNPY5RC5AR1 | |
| SCHEMBL30152128 | 0.94 | NPY4R (0.47) | NPY4RNPY1RNPY2RNPY5RC5AR1 | |
| SCHEMBL29420164 | 0.94 | NPY4R (0.47) | NPY4RNPY1RNPY2RNPY5RC5AR1 | |
| SCHEMBL29461968 | 0.94 | NPY4R (0.46) | NPY4RNPY1RNPY2RNPY5RKISS1R | |
| SCHEMBL30948383 | 0.93 | NPY4R (0.45) | NPY4RNPY1RNPY2RNPY5RGLP1R | |
| SCHEMBL29464056 | 0.92 | NPY4R (0.49) | NPY4RNPY1RNPY2RNPY5RC5AR1 | |
| SCHEMBL31252942 | 0.92 | NPY4R (0.49) | NPY4RNPY1RNPY2RNPY5RC5AR1 | |
| SCHEMBL29591109 | 0.92 | NPY4R (0.44) | NPY4RNPY1RNPY2RNPY5RC5AR1 | |
| SCHEMBL30475878 | 0.91 | NPY4R (0.46) | NPY4RNPY1RNPY2RNPY5RGLP1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240083962-A1 | AGENT FOR PROMOTING ANGIOGENESIS AND METHODS AND USES THEREOF | VASOMUNE THERAPEUTICS INC (CA) | 2024-03-14 | — | — | US | claimed |
| CN-110225922-B | Agents for promoting angiogenesis and methods and uses thereof | 血管免疫治疗公司 | 2023-09-12 | — | — | CN | claimed |
| EP-4132491-A2 | CORONAVIRUS THERAPEUTICS AND TREATMENT METHODS | Vasomune Therapeutics Inc. (CA) | 2023-02-15 | — | — | EP | claimed |
| CN-115666543-A | Coronavirus therapeutic agents and methods of treatment | 血管免疫治疗公司 | 2023-01-31 | — | — | CN | claimed |
| EP-3568409-B1 | AGENT FOR PROMOTING ANGIOGENESIS AND USES THEREOF | VASOMUNE THERAPEUTICS INC (CA) | 2022-12-21 | — | — | EP | claimed |
| US-20220372095-A1 | AN AGENT FOR PROMOTING ANGIOGENESIS AND METHODS AND USES THEREOF | VASOMUNE THERAPEUTICS INC (CA) | 2022-11-24 | — | — | US | claimed |
| US-20250345387-A1 | CORONAVIRUS THERAPEUTICS AND TREATMENT METHODS | HAMILTON DOUGLAS A (US) | 2025-11-13 | — | — | US | disclosed |
| US-20240083962-A1 | AGENT FOR PROMOTING ANGIOGENESIS AND METHODS AND USES THEREOF | VASOMUNE THERAPEUTICS INC (CA) | 2024-03-14 | — | — | US | disclosed |
| CN-110225922-B | Agents for promoting angiogenesis and methods and uses thereof | 血管免疫治疗公司 | 2023-09-12 | — | — | CN | disclosed |
| EP-4132491-A2 | CORONAVIRUS THERAPEUTICS AND TREATMENT METHODS | Vasomune Therapeutics Inc. (CA) | 2023-02-15 | — | — | EP | disclosed |
| CN-115666543-A | Coronavirus therapeutic agents and methods of treatment | 血管免疫治疗公司 | 2023-01-31 | — | — | CN | disclosed |
| US-20230028130-A1 | Coronavirus Therapeutics and Treatment Methods | HAMILTON DOUGLAS A (US) | 2023-01-26 | — | — | US | disclosed |
| EP-3568409-B1 | AGENT FOR PROMOTING ANGIOGENESIS AND USES THEREOF | VASOMUNE THERAPEUTICS INC (CA) | 2022-12-21 | — | — | EP | disclosed |
| US-20220372095-A1 | AN AGENT FOR PROMOTING ANGIOGENESIS AND METHODS AND USES THEREOF | VASOMUNE THERAPEUTICS INC (CA) | 2022-11-24 | — | — | US | disclosed |
| US-11384130-B2 | Agent for promoting angiogenesis and methods and uses thereof | VASOMUNE THERAPEUTICS INC. (CA) | 2022-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230028130-A1 | Coronavirus Therapeutics and Treatment Methods | SARS1, ACE2, TMPRSS2 | NPY4R 3436/4885NPY1R 3374/4885NPY2R 3873/4885 |
| US-20220372095-A1 | AN AGENT FOR PROMOTING ANGIOGENESIS AND METHODS AND USES THEREOF | VEGFA, PGF, FLT4 | NPY4R 1467/4885NPY1R 1480/4885NPY2R 1651/4885 |
| US-20250345387-A1 | CORONAVIRUS THERAPEUTICS AND TREATMENT METHODS | SARS1, ACE2, TMPRSS2 | NPY4R 3436/4885NPY1R 3374/4885NPY2R 3873/4885 |
| US-20240083962-A1 | AGENT FOR PROMOTING ANGIOGENESIS AND METHODS AND USES THEREOF | VEGFA, PGF, FLT4 | NPY4R 1433/4885NPY1R 1507/4885NPY2R 1650/4885 |
| US-11384130-B2 | Agent for promoting angiogenesis and methods and uses thereof | VEGFA, PGF, FLT4 | NPY4R 1433/4885NPY1R 1507/4885NPY2R 1650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.